臨床外科68巻8号

2013年08月発行

特集 外科医のための癌免疫療法―基礎と臨床 臨床編

メラノーマの免疫学と免疫療法の進歩

著者： 斎田俊明¹

所属機関： ¹信州大学医学部皮膚科

ページ範囲：P.915 - P.919

【ポイント】

◆先駆的な免疫学的研究が進められたにもかかわらず，進行期メラノーマに有効な治療法は存在しなかった．しかし最近，予後改善を期待できる画期的な新薬が登場した．

◆免疫抑制解除作用を有する新薬イピリムマブ（抗CTLA-4抗体）によって進行期メラノーマ患者の生存期間が有意に延長する．抗PD-1抗体も有望である．

◆メラノーマの分子遺伝学的研究が進み，変異BRAFの分子標的薬vemurafenibをはじめ，臨床効果を期待できる新薬の開発が進んでいる．

参考文献

1）斎田俊明：ダーモスコピーのすべて：皮膚科の新しい診断法．南江堂，2012

2）日本皮膚悪性腫瘍学会（編）：皮膚悪性腫瘍診療ガイドライン第1版．金原出版，2007

3）Eton O, Legha SS, Bedikian AY, et al：Sequential biochemotherapy versus chemotherapy for metastatic melanoma：results from a phase III randomized trial. J Clin Oncol 20：2045-2052, 2002

4）Atkins MB, Lotze MT, Duthcer JP, et al：High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma：analysis of 270 patients treated between 1985 and 1933. J Clin Oncol 17：2015-2016, 1999

5）Morton DL, Eilber FR, Holmes EC, et al：BCG immunotherapy of malignant melanoma：summary of a seven-year experience. Ann Surg 180：635-643, 1974

6）Cahan LD, Irie RF, Singh R, et al：Identification of a human neuroectodermal tumor antigen（OFA-I-2）as ganglioside. Proc Natl Acad Sci USA 79：7629-7633, 1982

7）Boon T, Cerottini JC, van den Eynde B, et al：Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12：337-365, 1994

8）Kawakami Y, Eliyahu S, Sakaguchi K, et al：Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180：347-352, 1994

9）Nestle FO, Alijagic S, Gilliet M, et al：Vaccination of melanoma patients with peptide- or lysate-pulsed dendritic cells. Nat Med 4：328-332, 1998

10）Nagayama H, Sato K, Morishita M, et al：Results of a phase I clinical study using autologous tumor lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13：521-530, 2003

11）Dudley ME, Yang JC, Sherry R, et al：Adoptive cell therapy for patients with metastatic melanoma：evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26：5233-5239, 2008

12）Hodi FS, O'Day SJ, McDermott DF, et al：Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363：711-723, 2010

13）Robert C, Thomas I, Bondarenko J, et al：Ipilimimab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364：2517-2626, 2011

14）Wolchok J, Hoos A, O'Day SJ, et al：Guidelines for the evaluation of immune-related activity in solid tumors：immune-related response criteria. Clin Cancer Res 15：7412-7420, 2009

15）Tapalian SL, Hodi FS, Brahmer JR, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366：2443-2454, 2012

16）Brahmer JR, Tykodi SS, Chow LQM, et al：Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366：2455-2465, 2012

17）Curtin JA, Fridlyand J, Kageshita T, et al：Distinct sets of genetic alterations in melanoma. N Engl J Med 353：2135-2147, 2005

18）Chapman PB, Hauschild A, Robert C, et al：Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med 364：2507-2516, 2011

19）Khalili JS, Lin S, Rodriguez-Cruz TG, et al：Oncogenic BRAFV600E promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18：5329-5340, 2012